Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca returns oncology programme rights to Infinity

This article was originally published in Scrip

Executive Summary

AstraZenecahas returned the rights to Infinity Pharmaceuticals' Hsp90 inhibitor programme after reviewing the products' potential and weighing up competing R&D investment priorities. The programme includes IPI-504 (retaspimycin hydrochloride for injection), which is currently in Phase III registration trials for patients with refractory gastrointestinal stromal tumours and oral IPI-493, which is in a Phase I study in patients with advanced solid tumours. Infinity will continue to develop the two products as it believes that with a prospective first-to-market Hsp90 inhibitor in late-stage development it can accelerate the timeframe for the company to achieve a meaningful commercial presence, Adelene Perkins, president and chief business officer, said. AstraZeneca will continue to fund an amount equivalent to its share of the Hsp90 programme costs for the next six months and Infinity will pay royalties on future net sales of IPI-504 and IPI-493. AstraZeneca acquired the worldwide rights to the two products when it acquired MedImmunelast year. MedImmune previously acquired the rights in August 2006.

You may also be interested in...



Myotec and Hybrid merge to form PsiOxus

Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.

Trophos's MitoCare programme receives €6 million EU funding

A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.

Novartis and Alcon reach compromise to settle merger saga

Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.

Topics

Related Companies

UsernamePublicRestriction

Register

SC007664

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel